


ATTACHMENT 1

Claims on Appeal:

3. A N^1 -monosubstituted polyamine analogue or derivative represented by the formula



wherein R is selected from a D or L amino acid; D or L ornithine, an alicyclic, a single or multi-ring aromatic; aliphatic-substituted single or multi-ring aromatic; and a substituted or unsubstituted, single or multi-ring heterocyclic and

Ansmt 10/13/2005

wherein said analogue or derivative does not have a formula represented by ID 1022, 1043, or 1202.

2
3. An analogue or derivative according to claim 3 wherein R is a D or L amino acid or D or L ornithine.

1
3. A composition comprising a polyamine analogue or derivative according to claim 3, 32 or 33 and a pharmaceutically acceptable excipient.

4
3. A composition comprising a polyamine analogue or derivative according to claim 3, a pharmaceutically acceptable excipient, and an inhibitor of polyamine synthesis.

5
3. A composition according to claim 3 herein said inhibitor of polyamine synthesis is difluoromethylornithine (DFMO).

6
3. A method for treating a disease or a condition in a subject associated with undesired cell proliferation and/or which is treatable by inhibition of polyamine transport, comprising administering to said subject a polyamine analogue or derivative according to claim 3.

7
3. A method according to claim 3 wherein said undesired cell proliferation is associated with proliferation of cells of the immune system, cells of the vascular neointima, tumor cells or with undesired angiogenesis.

8
3. A method according to claim 3 wherein said disease or condition is cancer or post-angioplasty injury.

9
3. A method according to claim 3 further comprising administration of an inhibitor of polyamine synthesis.

1. 41. A method according to claim 40 wherein said inhibitor of polyamine synthesis is difluoromethylornithine (DFMO).

2. 42. A composition according to claim 38 or 39 in solid form

3. 43. A composition according to claim 35 or 36 in liquid form.

4. 44. A method according to any one of claims 39-41 wherein said administering is performed orally, parenterally, topically, transdermally, intravaginally, intranasally, intrabronchially, intracranially, intraocularly, intraaurally, or rectally, or by injection.

5. 45. A method according to claim 44 wherein said administering by injection is intravenous, subcutaneous, intramuscular, intracranial, or intraperitoneal.

6. 46. A composition comprising a polyamine analogue or derivative according to claim 46 and a pharmaceutically acceptable excipient.

7. 48. A method for treating a disease or a condition in a subject comprising administering to said subject a polyamine analogue or derivative according to claim 46.

add
C 4

49. (New) The analogue or derivative of claim 3, wherein said substituted or unsubstituted heterocyclic is a pyrrolidine or a substituted pyrrolidine.

50. (New) The analogue or derivative of claim 49, wherein said substituted pyrrolidine is an N-substituted pyrrolidine.

51. (New) The analogue or derivative of claim 50 represented by the formula ID 1158.

52. (New) The analogue or derivative of claim 3 represented by the formula ID 1224.

53. (New) A method according to claim 37 wherein said condition is associated with cancer.